Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

7 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Immunomodulation with pomalidomide at early lymphocyte recovery after induction chemotherapy in newly diagnosed AML and high-risk MDS.
Zeidner JF, Knaus HA, Zeidan AM, Blackford AL, Montiel-Esparza R, Hackl H, Prince GT, Gondek LP, Ghiaur G, Showel MM, DeZern AE, Pratz KW, Douglas Smith B, Levis MJ, Gore S, Coombs CC, Foster MC, Streicher H, Karp JE, Luznik L, Gojo I. Zeidner JF, et al. Among authors: douglas smith b. Leukemia. 2020 Jun;34(6):1563-1576. doi: 10.1038/s41375-019-0693-4. Epub 2020 Jan 3. Leukemia. 2020. PMID: 31900407 Free PMC article. Clinical Trial.
Myelodysplastic syndromes: what do hospitalists need to know?
Zeidan AM, Faltas B, Douglas Smith B, Gore S. Zeidan AM, et al. Among authors: douglas smith b. J Hosp Med. 2013 Jun;8(6):351-7. doi: 10.1002/jhm.2049. Epub 2013 May 11. J Hosp Med. 2013. PMID: 23666619 Free PMC article. Review.
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results.
Cortes JE, Douglas Smith B, Wang ES, Merchant A, Oehler VG, Arellano M, DeAngelo DJ, Pollyea DA, Sekeres MA, Robak T, Ma WW, Zeremski M, Naveed Shaik M, Douglas Laird A, O'Connell A, Chan G, Schroeder MA. Cortes JE, et al. Among authors: douglas smith b. Am J Hematol. 2018 Nov;93(11):1301-1310. doi: 10.1002/ajh.25238. Epub 2018 Sep 9. Am J Hematol. 2018. PMID: 30074259 Free PMC article. Clinical Trial.
A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia.
Zeidner JF, Lin TL, Vigil CE, Fine G, Yair Levy M, Nazha A, Esteve J, Lee DJ, Yee K, Dalovisio A, Wang ES, Bergua Burgues JM, Schriber J, Litzow MR, Frankfurt O, Castillo TBD, Bhatt VR, Bhatnagar B, Mehta P, Dillon R, Vicente MV, Anthony S, Bearss D, Montesinos P, Douglas Smith B. Zeidner JF, et al. Among authors: douglas smith b. Blood Cancer J. 2021 Oct 30;11(10):175. doi: 10.1038/s41408-021-00568-3. Blood Cancer J. 2021. PMID: 34718324 Free PMC article. Clinical Trial. No abstract available.
Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia.
Cortes JE, Muresan B, Mamolo C, Cappelleri JC, Crescenzo RJ, Su Y, Gambacorti-Passerini C, Heeg B, Douglas Smith B. Cortes JE, et al. Among authors: douglas smith b. Curr Med Res Opin. 2019 Sep;35(9):1615-1622. doi: 10.1080/03007995.2019.1605239. Epub 2019 May 15. Curr Med Res Opin. 2019. PMID: 30964361
An empirical study of religious mysticism.
Douglas-Smith B. Douglas-Smith B. Br J Psychiatry. 1971 May;118(546):549-54. doi: 10.1192/bjp.118.546.549. Br J Psychiatry. 1971. PMID: 5580372 No abstract available.